Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Single Product, Single Price Trade Ratio in H1 FY2020 Virtually Flat: MHLW
November 25, 2020
- Ryukaikon Confab Held after 17 Month Hiatus, COVID-19 Impact on Drug Distribution Discussed
November 25, 2020
- MHLW to Issue COVID-19 Immunity Certificate: Parliamentary Secretary
November 25, 2020
- MHLW to Prepare 7,500 More Freezers for COVID-19 Vaccine Storage at Medical Institutions
November 25, 2020
- MHLW Weighing Fixed Brand Vaccine Allocation for Each Medical Institution: Official
November 25, 2020
- COVID-19 Vaccine Distribution Will Be Undertaken by Wholesalers with Certain Track Records: Minister
November 25, 2020
- Takeda’s ALK Med, 1st Male Indication for HPV Vaccine, Lynparza’s Pancreatic Cancer Use Up for PAFSC Review on Dec. 4
November 24, 2020
- 1st Humira Biosimilar to Join NHI Price List on Nov. 25
November 24, 2020
- MHLW to Evaluate Suspected Adverse Reactions to COVID-19 Vaccines More Frequently than Usual: Minister
November 24, 2020
- Govt Won't Disclose Plans for Excess COVID-19 Vaccines: Health Minister
November 24, 2020
- LDP Going into Tax Reform Debate for FY2021
November 20, 2020
- Fully Implement Off-Year Drug Re-Pricing: LDP Fiscal Consolidation HQ
November 20, 2020
- Lower House Passes Immunization Act Amendment Bill
November 20, 2020
- PAFSC Likely to Skip Review of Ono’s Cancer Cachexia Drug Yet Again
November 20, 2020
- Lilly’s Galcanezumab Up for PAFSC Review for Migraine Prevention on Dec. 2
November 19, 2020
- MHLW Mulls Health Follow-Up on 10,000-Plus COVID-19 Vaccine Recipients
November 19, 2020
- MHLW Expects Use of Dry Ice-Fitted Cooling Boxes to Deliver Ultracold Chain-Required COVID-19 Shots: Official
November 19, 2020
- Chuikyo Healthcare, Payer Reps Still Divided Over Off-Year Re-Pricing Debate
November 19, 2020
- Japan Should Consider Mass Vaccinations for COVID-19: JMA Official
November 18, 2020
- MHLW Collecting Evidence to Discuss Introduction of Medical Fee for Hospital Formularies in FY2022 Reimbursement Reform
November 18, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…